In a press release on Tuesday, the Danish company stated that, due to significant early signs of efficacy, they will stop the trial of Ozempic, a type 2 diabetes treatment, a year early.
Novo Nordisk´s shares are up 3.1% at the time of writing and are currently worth 670 DKK in Copenhagen.
The press release further states that the decision to halt one of the trial´s stages early, which will result in the whole process being done a year faster than expected, was based on a recommendation from the Independent Monitoring Committee (DMC).
According to the DMC, results from an interim analysis met a pre-specified criteria that allows Novo to stop the trial stage early.
Novo Nordisk is well-known for Wegony, a weight-loss drug that was found to have significant cardiovascular benefits in August. Since then, the company has seen its shares rise by almost 17%.
In August, the Danish government stated that Novo Nordisk alone had lifted the country’s economic growth forecast by 0.6%.
Novo Nordisk is now Europe’s highest valued listed company and is worth around €385 billion.